
1. elife. 2014 nov 19;3. doi: 10.7554/elife.03582.

a genetically attenuated malaria vaccine candidate based p. falciparum
b9/slarp gene-deficient sporozoites.

van schaijk bc(1), ploemen ih(1), annoura t(2), vos mw(1), foquet l(3), van
gemert gj(1), chevalley-maurel s(2), van de vegte-bolmer m(1), sajid m(2),
franetich jf(4), lorthiois a(4), leroux-roels g(3), meuleman p(3), hermsen cc(1),
mazier d(4), hoffman sl(5), janse cj(2), khan sm(2), sauerwein rw(1).

author information: 
(1)department medical microbiology, radboud university nijmegen medical
center, nijmegen, netherlands.
(2)leiden malaria research group, parasitology, leiden university medical center,
leiden, netherlands.
(3)center vaccinology, ghent university university hospital, ghent,
belgium.
(4)centre d'immunologie et des maladies infectieuses, université pierre et marie 
curie-paris 6, paris, france.
(5)sanaria inc., rockville, united states.

a highly efficacious pre-erythrocytic stage vaccine would important tool
for control elimination malaria currently unavailable.
high-level protection humans achieved experimental immunization with
plasmodium falciparum sporozoites attenuated radiation anti-malarial 
drug coverage. immunization genetically attenuated parasites (gap) would 
an attractive alternative approach. study, present data safety 
protective efficacy using sporozoites deletions two genes, the
newly identified b9 slarp, govern independent critical processes
for successful liver-stage development. rodent malaria model,
pbδb9δslarpgap completely attenuated showing breakthrough infections while
efficiently inducing high-level protection. human pfδb9δslarpgap generated
without drug resistance markers infective human hepatocytes vitro 
to humanized mice engrafted human hepatocytes vivo completely aborted
development infection. findings support clinical development a
pfδb9δslarpspz vaccine.

doi: 10.7554/elife.03582 
pmcid: pmc4273440
pmid: 25407681  [indexed medline]

